AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma: a Prospective, Open-label Single-arm, Exploratory Trial.

NCT05033587 Phase 2 UNKNOWN

This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed glioblastoma.

Details

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase	Phase 2
Status	UNKNOWN
Enrolment	28
Start date	2021-09
Completion	2023-11-01

Conditions

• MGMT-Unmethylated Glioblastoma

Interventions

• Anlotinib
• AK105
• Radiotherapy

Primary outcomes

• PFSR-6m — up to 6 months
  Progression-Free Survival rate at 6 months.

Countries

China